Accolade, Inc. ACCD shares are trading lower after-hours on Wednesday after the company announced results for the second-quarter 2024 and issued guidance.
What To Know: The company posted second-quarter earnings of losses of 43 cents per share and sales of $96.90 million, beating the $94.09 million estimate.
Accolade anticipates third-quarter revenue to be in a range between $95 million and $97 million, versus the $96.57 million estimate. The company sees full-year 2024 revenue between $410 million and $414 million, versus the $412.52 million estimate.
"We are halfway through the 2024 fiscal year and the demand environment for our solutions remains strong. Accolade continues to lay the foundation to build a lasting, scalable business that will improve people's lives and fundamentally change the way healthcare is experienced in this country. Accolade's unique combination of advocacy and care solutions is changing the way employers deliver healthcare to their employees and their families, and the success of this strategy is evident in our growing customer base which now totals more than 1,000 customers," said Rajeev Singh, Accolade CEO.
"By providing the benefits advocacy and navigation services that members need to fully leverage their healthcare options, as well as operating a large and growing care delivery organization, we are closing the critical gaps in the care experience that impact health outcomes, costs of care, and the overall healthcare experience."
Related Link: Why Lithium Americas Stock Plunged Today
ACCD Price Action: Shares of ACCD were down 9.23% at $8.85 in the after-hours session at the time of publication, according to Benzinga Pro.
Image by Mohamed Hassan from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
